about
the potential factors that could affect the Company's business and
financial results is included in the Company's filings, available via the
United States Securities and Exchange Commission.
-- FINANCIAL TABLES FOLLOW --
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES
Unaudited Consolidated Statements of Operations
Three Months Ended December 31,
2007 2006
(restated)
Revenues $ 19,223,779 $ 11,128,000
Cost of Goods Sold 10,940,507 8,647,623
Gross Profit 8,283,272 2,480,377
Operating Expenses
Selling 3,595,460 1,839,251
Research and development 862,519 96,833
General and administrative 382,646 684,888
Total operating expenses 4,840,625 2,620,972
Income (Loss) from Operations 3,442,647 (140,595)
Other Income (Expense)
Other income (expense) 2,102,115 --
Interest expense, net (427,800) (17,114)
Total other income (expense) 1,674,315 (17,114)
Income (Loss) Before Provision
for Income Tax 5,116,962 (157,709)
Net Income (Loss) $ 5,116,962 $ (157,709)
Basic Earnings Per Share $ 0.12 $ (0.00)
Diluted Earnings Per Share $ 0.12 $ (0.00)
Basic Weighted Average Shares
Outstanding 41,
'/>"/>
SOURCE Lotus Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine news :1.
Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing2.
Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies3.
Lotus Pharmaceuticals Raises $5 Million in Private Placement4.
Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results5.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma6.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference7.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.8.
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study9.
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum10.
ACG Announces Major Gift by Salix Pharmaceuticals, Inc.11.
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors